Meridian Enterprises Private Limited

Meridian Enterprises Private Limited, established on March 5, 1990, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24231MH1990PTC055663. It operates as a non-government company with an authorized capital of ₹1.25 crore and a paid-up capital of ₹50 lakh. As of the latest available data, Meridian Enterprises employs approximately 443 professionals.

The company's registered office is located at 1108 Embassy Centre, Nariman Point, Mumbai, Maharashtra, 400021. Meridian Enterprises specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, it has built a reputation for innovation and quality in the pharmaceutical industry.

Meridian Enterprises operates manufacturing facilities in Mumbai, Maharashtra. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed. However, the company's focus on innovation and quality suggests that its manufacturing processes adhere to stringent industry standards.

The leadership team at Meridian Enterprises Private Limited includes:

• Sandeep Ramesh Banatwala: Managing Director, appointed on October 30, 2006.

• Jyotsna Ramesh Banatwala: Director, appointed on March 5, 1990.

• Sonia Banatwala: Whole-Time Director, appointed on May 29, 1998.

• Nilesh Pravinchandra Damania: Director, appointed on March 23, 2023.

• Ryan Anthony Wood: Director, appointed on March 23, 2023.

• Anand Uttam Fandate: Director, appointed on March 23, 2023.

These individuals bring a wealth of experience and leadership to the company, contributing to its growth and success in the pharmaceutical industry.

Meridian Enterprises Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports finished pharmaceutical formulations, such as Miconazole and Indomethacin, to these regions. In the United States, Meridian Enterprises has registered its manufacturing facilities with the FDA, ensuring compliance with Good Manufacturing Practices (GMP). The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access. In the European Union and the United Kingdom, Meridian Enterprises holds EU GMP certificates, demonstrating adherence to European quality standards. While specific details regarding approvals in Australia and Japan are not publicly available, the company's compliance with international standards suggests a commitment to meeting regulatory requirements in these markets.

Meridian Enterprises Private Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to these regions, reflecting its strategic focus on global market penetration. While specific details regarding WHO prequalification are not publicly disclosed, the company's adherence to international quality standards suggests a commitment to meeting the requirements for WHO prequalification, thereby enhancing access to these emerging markets.

Meridian Enterprises Private Limited demonstrates a diversified geographic strategy by exporting its products to various regions, including the United States, European Union, United Kingdom, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and positions the company to leverage growth opportunities across different markets. The company's focus on both developed and emerging markets indicates a strategic direction aimed at achieving balanced global expansion.

Meridian Enterprises Private Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with Good Manufacturing Practices (GMP). The company has filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. Specific details regarding the number of approved ANDAs, Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to FDA regulations underscores its commitment to maintaining high-quality standards for its products.

Meridian Enterprises Private Limited holds EU GMP certificates, demonstrating adherence to European quality standards. While specific details regarding WHO prequalification are not publicly disclosed, the company's compliance with international quality standards suggests a commitment to meeting the requirements for WHO prequalification, thereby enhancing access to global markets.

Meridian Enterprises Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company has obtained approvals from state drug controllers for its products, facilitating domestic market access. Specific details regarding export No Objection Certificates (NOCs) are not publicly available. However, the company's adherence to CDSCO regulations underscores its commitment to maintaining high-quality standards for its products.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Meridian Enterprises Private Limited. This absence suggests that the company maintains a strong compliance record with regulatory authorities.

In the therapeutic categories of Antifungals and Analgesics & Antipyretics, Meridian Enterprises Private Limited faces competition from several established pharmaceutical companies. While specific market share data is not publicly available, the company's export data indicates a focus on Miconazole and Indomethacin, which are commonly used in these therapeutic areas. The company's adherence to international quality standards and its diversified geographic strategy position it to effectively compete in these markets.

Meridian Enterprises Private Limited's key differentiators include its commitment to innovation, as evidenced by its introduction of unique formulations such as the saline nasal decongestant product. The company's adherence to high ethical standards and focus on customer satisfaction further distinguish it in the pharmaceutical industry. Additionally, its diversified product portfolio and global market presence enhance its competitive advantage.

Meridian Enterprises Private Limited's current strategic direction focuses on the manufacturing and export of generic pharmaceutical formulations, with an emphasis on Antifungals and Analgesics & Antipyretics. The company's future outlook includes expanding its product portfolio, enhancing its presence in emerging markets, and pursuing opportunities in specialty pharmaceuticals and Contract Development and Manufacturing Organizations (CDMO) services.

Meridian Enterprises Private Limited has a track record of consistent export activity, with a total export value of $541,000 USD across 19 shipments. The company's portfolio concentration, with its top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The company's adherence to international quality standards and its diversified geographic strategy suggest reliability and consistency in its operations.

Importers should verify the following certifications when considering Meridian Enterprises Private Limited as a supplier:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• EU GMP Certificate: Verify the company's compliance with European Good Manufacturing Practices.

• WHO Prequalification: Check for WHO prequalification status to ensure adherence to international quality standards.

• ISO Certifications: Assess the company's compliance with relevant ISO standards for quality management.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When conducting due diligence on Meridian Enterprises Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's certifications and registrations with relevant regulatory authorities.

• Assess Financial Stability: Review the company's financial statements and credit ratings to evaluate financial health.

• Evaluate Product Quality: Request product samples and conduct quality assessments to ensure they meet required standards.

• Review Supply Chain Practices: Assess the company's supply chain for reliability and consistency.

• Check References: Obtain feedback from existing clients and partners regarding their experiences with the company.

Be cautious of any discrepancies in regulatory certifications, unexplained financial irregularities, or negative feedback from references, as these may indicate potential risks.